Ilya Pharma is one of ten life science companies selected this year for Springboard Enterprises’ Health Innovation Hub: Life Science. The company joins over 800 experienced “been there, run that”
Nordic Life Science
NLS Pharma News
Pharma
AstraZeneca will collaborate with Accent Therapeutics to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. This collaboration focuses on targeting RMPs, proteins that
The pharma company has lately announced several encouraging results from its ongoing clinical trials in lung cancer, gastric cancer, colorectal cancer and liver cancer. The Phase III ADAURA trial showed
Calliditas Therapeutics has launched an investor roadshow for a contemplated initial public offering of American Depositary Shares in the United States for trading on The Nasdaq Global Market in the
Sigrid Therapeutics has announced that pharmaceutical R&D leader, Dr. Jan Lundberg has joined the company as an investor and member of the Scientific Advisory Board. Jan Lundberg has more than
Medivir has announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company. Yilmaz Mahshid has long and broad experience from qualified roles in
Clinical trials
Follicum has announced that the clinical Phase IIa study with a cream-like formulation of FOL-005 will re-start, following a pause due
BerGenBio has announced that dosing has commenced in the Phase II clinical trial assessing bemcentinib in hospitalized COVID-19 patients. Bemcentinib
The pharma company has lately announced several encouraging results from its ongoing clinical trials in lung cancer, gastric cancer, colorectal
Oncopeptides has announced completion of enrollment in the phase 3 study OCEAN for the treatment of relapsed refractory multiple myeloma.
The Swedish life science industry organization SwedenBIO has released its Drug Discovery and Development Pipeline report, highlighting the state of the
The first participants have been enrolled into a Phase 1/2 clinical trial of NVAX-CoV2373 which is being conducted at sites
Researchers at Karolinska Institutet are coordinating a multi-national clinical trial that will evaluate the effect of hyperbaric oxygen treatment (HBO)
Gesynta Pharma has reported positive Phase I results with GS-248 for the treatment of microvascular disease. The Phase I study
Galecto has recruited more than 150 patients in its Phase 2b GALACTIC-1 study of GB0139 in Idiopathic Pulmonary Fibrosis (IPF).
AstraZeneca and the University of Oxford have announced an agreement for the global development and distribution of the University’s potential
BerGenBio has announced that bemcentinib has been selected as the first potential treatment to be fast-tracked in a new UK
Alligator Bioscience has presented the status of its ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed
AstraZeneca and MSD have announced positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic
Saniona has announced results from its 24-week double blind, randomized, placebo-controlled Phase 2 trial evaluating the safety and efficacy of
AstraZeneca’s Tagrisso Phase III ADAURA trial will be unblinded early after overwhelming efficacy in the adjuvant treatment of patients with
Spago Nanomedical has momentarily halted its clinical study SPAGOPIX-01 at Uppsala University Hospital due to the COVID-19 pandemic. Uppsala University
Profiles in Pharma
InDex Pharmaceuticals recently announced conclusions from its CONDUCT study, evaluating their TLR9 agonist cobitolimod for the treatment of moderate to
BioArctic’s lead compound has the potential to become the first disease-modifying treatment for Alzheimer’s, and so far the company’s journey
Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new
She joined LEO Pharma by chance, more than 27 years ago, but she remained there, for the true focus on
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Logistics
The best pharmaceuticals and medical supplies on the market are useless to patients unless they arrive at their destinations intact, unspoiled and on time. The proper packaging and shipping of
Two global life science firms share some of their projects and logistical solutions to deliver healthcare to parts of the world where it is needed the most. Cardiovascular disease is